MAPT and Alzheimer disease: Experimental studies provide mechanistic insights, suggesting that PD may contribute to AD pathology through chronic systemic inflammation, amyloid-β and tau aggregation, neuroinvasion of Pg, and oral–gut–brain microbiome dysregulation.